Nuvalent
NUVL
Performance
About Nuvalent
Nuvalent is a biotechnology company focused on developing precisely targeted cancer therapies. It applies chemistry and structure-based drug discovery to design small molecules that selectively inhibit kinase targets, addressing resistance and selectivity challenges in oncology. The company collaborates with physician-scientists to identify patient needs and improve existing treatment options. Based in Cambridge, Massachusetts, Nuvalent advances targeted therapies through clinical development and translational research to serve cancer patients.
Recent News
GSK to Acquire Nuvalent for $10.6 B, Bolstering Oncology Pipeline
Markets News, June 9, 2026: Chip Stocks Pull Back as Nasdaq, S&P 500 End Lower; Trump Says US Must 'Respond' After Iran Shot Down Helicopter
GSK Shares Slip After Buying US Cancer Treatment Firm Nuvalent for $10.6bn
GSK to Acquire Nuvalent in $10.6 B Deal, Bolstering Lung Cancer Pipeline
InsideArbitrage Event Driven Monitor – June 9, 2026
GSK to Acquire Nuvalent for ~$10.6B
GSK Pursues $10.6bn Takeover of Cancer Biotech Nuvalent
Trio of Firms Guide GSK’s $10.6bn US Cancer Drug Maker Buy
STAT+: GSK to Buy Nuvalent, Maker of Targeted Cancer Drugs, for $10.6B
Gilead and Merck’s Latest Trial Success and Flop